Psychiatric Certificate Program


AzPA’s Psychiatric Certificate Training Program (PCP) is a practice-based activity designed for pharmacists in all practice settings. The intent of this training program is to provide additional training in the area of psychiatric pharmacy to enhance pharmacists’ clinical knowledge that can be applied directly to the patients they serve.


Course Goals

  • Provide training to enhance a practitioner’s ability to effectively assess, monitor, and manage the pharmacotherapy of patients with psychiatric disorders.
  • Deliver comprehensive medication therapy management to prevent, treat, and control psychiatric disorders using patient-centered care.
  • Promote appropriate and optimal medication use and adherence that minimizes drug interactions, poly pharmacy, and adverse effects.
  • Encourage healthy life styles and non-drug treatment approaches for optimizing a person’s mental and physical health.

How it Works


  • Self-Assessment: each participant must complete a self-assessment to gauge their comfort level of the material before completing the program. This will also be assessed again at the conclusion of the live seminar. 
  • Learning Modules: meant to ensure all participants have a basic understanding of psychiatric disorders. Each module has an assigned reading as well as a patient case that must be read and reviewed prior to the live seminar.
    • Module 1: Schizophrenia                                      
    • Module 2: Major Depressive Disorder      
    • Module 3: Bipolar Disorder                                  
    • Module 4: Anxiety Disorders 
    • Module 5: Sleep Disorders
    • Module 6: ADHD     
    • Module 7: Substance Related Disorders                  
  • Patient Case-Based Exercises (Patient Care Plan): There are patient based exercises at the end of each module that need to be completed as part of the content structure for this activity.  AzPA faculty will verify at the beginning of the live seminar that these plans were completed.
  • Examination: Each participant must complete an online examination and score a 70% or better to receive a passing grade. Do not start the test unless you plan to finish in one sitting.


  • The live training seminar includes didactic presentations as well as interactive training to practice comprehensive medication therapy management skills in the area of psychiatric disorders followed by a final examination.

Continuing Education

Activity Type: Knowledge Based

Target Audience: Pharmacists in all practice settings

Successful completion of the entire program will result in 25.5 contact hours of CPE credit (2.55 CEUs).

  • 17.5 hours (1.75 CEU) is awarded for completion of the home study learning portion | ACPE UAN: 0100-0000-19-039-H01-P
    • Initial Date of release: 4/15/2019 |  Expiration Date: 4/15/2022
  • 8 hours (0.8 CEU) is awarded for completion of the live training seminar. | ACPE UAN: 0100-0000-19-040-L01-P 
    • Initial date of release: 6/20/2019 | Expiration Date: 6/20/2022

Credits will be uploaded within 30 days from the live session date.  It is the participants responsibility to ensure your credits are uploaded within 60 days from the live session date.  After this time you will no longer be able to claim your CPE credit.

A Certificate of Achievement is awarded to participants who successfully complete all activity requirements:

  • Successful completion of the self-study component involves completing the self-assessments, the self-study activity, and passing the online exam with a score of 70% or above.
  • Successful completion of the live seminar component involves attending the full live seminar and and passing the final exam with a score of 70% or above. In addition, participants must complete a final program evaluation.

Key Learning Objectives 

  • Discuss the epidemiology and risk factors for the development of each selected psychiatric disorder.
  • Describe the typical clinical presentation of each selected psychiatric disorder.
  • Evaluate selected patient cases and determine whether a given patient exhibits signs and/or symptoms of each selected psychiatric disorders.
  • Describe the clinical course of each selected psychiatric disorder.
  • Compare and contrast the efficacy, safety, tolerability, monitoring parameters, and clinically significant drug interactions of pharmacologic treatment modalities commonly employed in the treatment of each selected psychiatric disorder.
  • Recommend appropriate initial medication therapy and therapeutic alterations/adjustments according to clinical practice guidelines.
  • Recognize and effectively manage common drug interactions associated with the treatment of each selected psychiatric disorders.
  • Formulate appropriate counseling information to be given to patients, or caregivers of patients, prescribed pharmacotherapy for the treatment of each selected psychiatric disorder.
  • Recommend strategies to minimize commonly experienced adverse drug events from prescribed medications.

Tentative Agenda

Morning | Part 1

  • Neuropharmacology and Pharmacodynamics
  • Schizophrenia
  • Bipolar Disorder
  • Major Depressive Disorder
  • Q&A

Afternoon | Part 2

  • Anxiety Disorders
  • Case 1: Depression and Anxiety
  • Sleep Disorders
  • Case II: Schizophrenia and Insomnia
  • Attention-Deficit/Hyperactivity Disorder
  • Case III: Bipolar Disorder and ADHD
  • Q&A

Our  Faculty

  • Martha Fankhauser, MS Pharm, FASHP, BCPP, Neuropsychiatric Pharmacy
  • Stephanie Lee, PharmD, BCPP, BCPS, Inpatient Mental Health Pharmacist
  • Nina Vadiei, PharmD, BCPP, Clinical Pharmacy Specialist in Psychiatry

Accreditation: The AzPA Psychiatric Certificate Training Program was developed by AzPA for pharmacists. The Arizona Pharmacy Association are accredited by the Accreditation Council for Pharmacy Education as providers of continuing education.